Join the DUPIXENT
at ACAAI 2020 DUP.20.10.0087
For Patients Ages 12+
Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus
DUPIXENT MyWay is a patient support program that helps ensure your eligible patients start and stay on DUPIXENT. DUPIXENT MyWay can help optimize access to DUPIXENT and provides:
Patient Access Support
Learn how to get your patients enrolled in DUPIXENT MyWay and download and fill out the form with your patients.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology
Putting the pieces together for acquiring DUPIXENT.
After you prescribe DUPIXENT, a correctly filled out DUPIXENT MyWay Enrollment Form helps ensure patient enrollments are processed without delays.
Forms are available at DupixentHCP.com. Please ensure that you are filling out the correct form that corresponds to the appropriate indication.
First, allow the patient to review the Patient Authorization and Certifications. Then, ensure the patient has signed and dated twice at the top of the form where indicated, as it is vital to the process that the patient reads and agrees to both the Patient Authorization and the Certifications.
To help ensure a seamless enrollment process, ask the patient if they would like to provide their email address, mobile phone number, and to consent to receiving text messages.
Please inform patients that DUPIXENT MyWay will be contacting them through their preferred method of communication and that maintaining communication is important for them to receive support from DUPIXENT MyWay.
Ensure that the Healthcare Provider has read and agrees to the Healthcare Provider certification, and signs and dates the prescription at the bottom.
Populate the clinical information corresponding to your patient’s diagnosis. A list of potential codes is provided within the Enrollment Form for reference. Be sure to provide only one ICD-10 code, even if the patient has comorbid disease.
Once the primary ICD-10 code is filled in and the form is completed, write the names of the patient and prescriber at the top of all pages.
DUPIXENT MyWay complements your office’s process for accessing DUPIXENT. Your office may choose to use a preferred specialty pharmacy to start the benefits investigation.
If this is the case, write the preferred specialty pharmacy name and then check the box indicating that you have sent the prescription to the specialty pharmacy, which will be responsible for securing the coverage on the patient’s behalf.
Fax the Enrollment Form with the checked box to both the specialty pharmacy and DUPIXENT MyWay. This will allow the specialty pharmacy to conduct the benefits investigation, and DUPIXENT MyWay will provide additional support to the patient.
If your office does not use a preferred specialty pharmacy, leave the box unchecked to indicate that you would like DUPIXENT MyWay to conduct the benefits investigation on the patient’s behalf.
Fax the Enrollment Form with the unchecked box to DUPIXENT MyWay. They will begin the benefits investigation and inform your office of the next steps.
Please note that you will receive a confirmation fax after sending the form.
If the patient has consented, the patient’s nurse educator will initiate a welcome call with the patient within a few days after enrolling. The DUPIXENT MyWay nurse connects patients to a variety of helpful resources, including one-on-one nursing support, financial assistance for eligible patients, and helpful refill and injection reminders.
Need additional guidance with the enrollment process? Contact your field access specialist or call DUPIXENT MyWay.
© 2020 Sanofi and Regeneron Pharmaceuticals, Inc.
All Rights Reserved.
Learn how to navigate the approval and specialty pharmacy process to help get your patients started on DUPIXENT.
VO: Putting the pieces together for acquiring DUPIXENT.
DUPIXENT is covered under the pharmacy benefit plan, which requires a patient to coordinate delivery with a specialty pharmacy.
After a healthcare provider prescribes DUPIXENT, the patient schedules their delivery of DUPIXENT from the specialty pharmacy,...
…pays the copay, coordinates the shipment, and can administer DUPIXENT themselves or receive the injection from a caregiver after appropriate training from their healthcare provider.
It’s important to understand the specialty pharmacy process and its role in obtaining DUPIXENT.
Many specialty medications, such as DUPIXENT, have longer turnaround times because of the prior authorization process.
When DUPIXENT is prescribed by a healthcare professional, you can work with the patient to complete the Enrollment Form, and then fax the Enrollment Form with all signatures, dates, and ICD-10 codes to DUPIXENT MyWay.
It is important that the patient consents to receiving communication from DUPIXENT MyWay and indicates how they would like to be contacted, whether it be via email, phone, or text.
Once enrolled, a benefits investigation to determine coverage begins.
It’s important to understand how to identify prescription drug coverage. Key points of contact for coverage are located on the card itself.
Some plans, including commercial and Medicare, may even have a separate pharmacy benefit card.
A Summary of Benefits Form will be faxed to your office within a few days, detailing the patient’s coverage—including prior authorization requirements and out-of-pocket costs. DUPIXENT MyWay will not conduct the benefits investigation, nor send a Summary of Benefits Form, for providers who have checked the specialty pharmacy box on the Enrollment Form, as this indicates that they wish the specialty pharmacy to conduct the benefits investigation.
DUPIXENT MyWay® can provide certain limited support
The prior authorization information required by the patient’s insurance to approve coverage for DUPIXENT may include the patient’s history, medication, and clinical information.
It is important to note that a plan may deny prior authorization. There are several reasons for this, including incomplete documentation, administrative errors, clinical reasons or a no-coverage determination, or a plan exclusion.
Approval is not guaranteed. Appealing the health plan’s denial does not always result in approval of DUPIXENT.
In the case of a denial, you may consider writing an appeal, if appropriate, making sure to address the plan’s specific concerns. You can refer to DupixentHCP.com for the appeals kit, which will provide information about the process of appealing a denial, and reference sample letters provided by DUPIXENT MyWay.
In some denial cases, a plan may require a peer-to-peer review with a medical reviewer at the health plan.
If the prior authorization is reviewed by the patient’s insurance carrier and is approved,...
...the prescription is triaged to the specialty pharmacy for fulfillment.
It is recommended that you fax a copy of prior authorization approval to DUPIXENT MyWay to help the office staff continue the process in several ways, such as:
Initiating contact with the patient regarding the approval and sharing the specialty pharmacy name and phone number.
Advising the patient to contact the specialty pharmacy for preferred delivery location.
And reminding them that the specialty pharmacy may call them from an unknown number.
Lastly, the specialty pharmacy reviews the prescription and contacts the patient to arrange for payment and delivery. If the patient is eligible for copay assistance, the patient or caregiver can then ensure the copay assistance is applied, coordinate delivery with the specialty pharmacy,...
VO: ...and access additional DUPIXENT MyWay support.
Once final approval and payment are received, the patient coordinates shipment to their home...
...or their healthcare provider’s office, depending on treatment plan.
Remember to monitor and document the patient’s progress for reauthorization. DUPIXENT MyWay will also remind the healthcare professional when the authorization is up for reapproval.
Need additional guidance with the enrollment process? Contact your Field Access Specialist or call DUPIXENT MyWay at 1-844-387-4936, Monday through Friday, 8 am to 9 pm Eastern Time.
© 2020 Sanofi and Regeneron Pharmaceuticals, Inc.
All Rights Reserved.